“Life-changing” APS Therapy machine pilot study shows significant benefits in pain relief and wide ranging improvements to wellbeing

emm and miranda

“Life-changing” APS Therapy machine pilot study shows significant benefits in pain relief and wide ranging improvements to wellbeing

 

Exciting news from Painfree Potential - one of our newest CMA Training School Members:

Action Potential Simulation, or APS Therapy, is the use of a micro-current machine, that sends a direct copy of the wave-form of ‘action potentials’, the body’s own electrical signals, through the cells, using electrodes attached to the skin. A two year pilot study, led by an MS Nurse with a background in holistic therapies, has been presented at the international conference CMSC, and accepted at the prestigious European conference, ECTRIMS, in September.

In the study’s participants, most of whom had MS, and many, chronic pain, 78% of people had a significant reduction in pain. Results ranged from no reduction, to 10 points on the visual analogue scale of 0-10. APS Therapy is by no means confined to use in MS, but there is excitement about the wide range of unexpected benefits that the study participants reported, with improvements in energy/fatigue, sleep quality, mobility, balance, cognition, mood and frequency of infection reported.

The mode of action of APS Therapy is to enhance cellular communication, and thus the removal of the products of inflammation. Various neuro-hormones and ATP are also boosted, which contribute to pain reduction and stimulate repair mechanisms.

 “One of the most exciting things for me, is seeing people able to reduce and withdraw from medications with such unacceptable side effects,” says author Miranda Olding, who now splits her time between working as an MS Specialist Nurse, and training therapists in APS Therapy in the UK. You can find out more at www.painfreepotential.co.uk

Reference: Matthews, E.M, Olding, M. (2016, June) Action Potential Simulation Therapy for Pain in People with Multiple Sclerosis: Report on a 2 Year Pilot Study. Poster presented at the Consortium of Multiple Sclerosis Centers, Washington, Maryland, US.

 




 

 

The COMPLEMENTARY MEDICAL ASSOCIATION (The CMA) © 2012. No part of this site may be reproduced without the express permission of The Complementary Medical Association. If used without prior consent a charge of US $1,000 per article, or mini section is paid (US $50 per word (minimum) will be charged. This is not meant to reflect a commercial rate for the content, but as a punitive cost and to reimburse The CMA for legal fees and time costs). Use of the contents, without permission will be taken as consent to bill the illegal user in full.